about
Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoformStructure-Guided Rescaffolding of Selective Antagonists of BCL-X LDiscovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimizationFragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitorsChemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic WindowDiscovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety.Inhibiting the deubiquitinating enzymes (DUBs).Targeting inhibitor of apoptosis proteins for therapeutic intervention.Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and roStructure-Based Design of GNE-495, a Potent and Selective MAP4K4 Inhibitor with Efficacy in Retinal Angiogenesis.USP7 small-molecule inhibitors interfere with ubiquitin binding.Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques.MAP4K4 regulates integrin-FERM binding to control endothelial cell motility.Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor ImmunityBio-inspired synthesis of xishacorenes A, B, and C, and a new congener from fuscolNK cells mediate clearance of CD8+ T cell-resistant tumors in response to STING agonistsDevelopment of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors
P50
Q27684307-7BF15E5F-B311-48BD-8488-E60B1E41AD30Q27684386-E07BFC1A-1992-4D62-82DC-8AD4F292E210Q27689638-3DC5696A-6E03-4BFD-8AF6-1D6EA67850CAQ27694795-3137823B-1A35-4FEA-805B-17B67370C4F5Q27704844-59E98142-B289-429C-8F41-43B92E36978AQ33418187-7A5CAC28-B59D-452E-AC7F-9E0D465D834BQ34506833-4CFAC490-E70E-4788-A20D-EE5BFFE0BB31Q35386992-2FEDC97B-9673-492B-A370-1BC494058D72Q37855868-29688124-98F9-473B-923E-B5A1D2D92A42Q39153790-2536C6F9-46A2-4FA5-8419-4E89694D8D20Q41761571-55F32ACD-C795-408B-B900-2268465FA1E4Q46429336-0886DB97-6520-4535-99B7-6B6D1C30BFD6Q46712370-62889C39-3502-4903-97A9-60ED8B8000A6Q46917529-19B507A4-E1BD-4764-B85C-A61D503F7C0CQ90428782-FA207D2A-AD4B-441D-BE30-680AFDADAA1AQ90535335-0400A116-7183-4F98-96C6-7799F3BE582EQ90540571-D8A511FB-7F07-45CC-97F4-CF9DE32AE5D6Q91973735-BAACCEB6-30F0-4586-B675-00F4C810BE44
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Chudi O Ndubaku
@ast
Chudi O Ndubaku
@en
Chudi O Ndubaku
@es
Chudi O Ndubaku
@nl
type
label
Chudi O Ndubaku
@ast
Chudi O Ndubaku
@en
Chudi O Ndubaku
@es
Chudi O Ndubaku
@nl
prefLabel
Chudi O Ndubaku
@ast
Chudi O Ndubaku
@en
Chudi O Ndubaku
@es
Chudi O Ndubaku
@nl
P106
P1153
8584121900
P31
P496
0000-0003-4183-0417